AXGN:NASDAQ
AxoGen, Inc Common Stock
$42.16
arrow_upward
+0.74%(+0.31) 1D
$42.16
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 11, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AXGN...
Open
$42.48
High
$42.59
Low
$39.62
Mkt. cap
2.27B
Avg. vol.
970.40K
Volume
3.48M
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.16
Shares outstanding
53.76M
No. of employees
622
Open
$42.48
High
$42.59
Low
$39.62
Mkt. cap
2.27B
Avg. vol.
970.40K
Volume
3.48M
52-wk high
$52.91
52-wk low
$15.27
EPS
-$0.68
Beta
1.16
Shares outstanding
53.76M
No. of employees
622
News stories
From web sources and news partners
GuruFocus
·
2 days ago
Axogen Inc (AXGN) Shares Fall 11.5% -- What GF Score of 64 Tells Investors
Stock Titan
·
2 days ago
AXGN 424B Filings - Axogen Inc SEC 424B
TipRanks
·
3 days ago
AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio
Dealroom
·
3 days ago
Axogen raises $210M in stock sale to fund BioCircuit deal
Profile
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
About AxoGen, Inc Common Stock
CEO-
Employees622
Founded2002
HeadquartersAlachua, Florida, United States
SectorMedical device
Websiteaxogeninc.com